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IL-4 has been shown to suppress acute graft vs. host disease (GVHD) in irradiated hosts. Here we evaluated
whether IL-4 suppresses acute GVHD in the un-irradiated parent-into-F1 GVHD model with relevance to renal
allograft rejection. IL-4 completely suppressed CD8 CTL when administered with donor cells however this effect
was lost if its administrationwas delayed 3 days. IL-4 did not inhibit donor CD8+ T cell homing to the host spleen
but rather prevented donor CD8+ T cell differentiation into CTLs. Studies with IL-4Rα-deficient donor cells or re-
cipient mice demonstrated that IL-4 effects on the host, rather than, or in addition to IL-4 effects on donor cells,
were critical for suppression of CTL. Because IL-4 decreased all splenic dendritic cell populations and increased
neutrophil and CD8+ T cells, IL-4may suppress donor CD8+ CTL by decreasing Ag presentation and/or increasing
host myeloid and CD8+ T cell suppression of donor T cells.









The parent-into-F1 model of acute graft-vs.-host disease (GVHD) is
useful for the study of in vivo CD8CTL development. The injection of ho-
mozygous parental T cells into fully MHC I + II disparate heterozygous
F1 mice induces the activation of donor CD4+ and CD8+ T cells specific
for hostMHC Ags. Donor CD8+ T cell activation andmaturation into CTL
effectors is initiated by a strong IL-2 response by the donor CD4+ T cells
[1]. This process is accompanied by a burst of IFN-γ, upregulation of Fas/
FasL expression, and acquisition of CTL effector markers, including
perforin. By day 14, spleens from recipient F1mice exhibit a typical “cy-
totoxic” or acute GVHD phenotype characterized by profound elimina-
tion of host B and T cells accompanied by engraftment of donor CD4+
and CD8+ T cells. Acute GVHD in this model can be blocked by costim-
ulatory blockade (CTLA4-Ig or combined anti-CD80/anti-CD86mAb) [2]
or IL-2 blockade [3] at the time of donor cell transfer.
The cytokines produced during GVHD have a profound effect on the
type of GVHD that develops. Blocking TNF prevents donor CTL
development and converts disease phenotype at two weeks from
acute cytotoxic to a chronic, stimulatory autoimmune phenotype (B
cell expansion, autoantibody production and engraftment of donor
CD4+ T cells but not CD8+ T cells) [4]. Blocking IFN-γ partially sup-
presses acute GVHD development by decreasing Fas/FasL expression
but only partially decreasing perforin expression [5]; this only partial
suppression of CTL function probably explains the failure of chronic
GVHD to develop in IFN-γ-suppressed mice. Treatment with IL-12 has
the opposite effect of IFN-γ and TNF suppression: it strongly stimulates
donor CD8+ CTL development and converts chronic GVHD to acute
GVHD [6].
Because the type 2 cytokine IL-4 generally antagonizes the effects of
IFN-γ and IL-12 and can inhibit CTL differentiation [7], it might be ex-
pected that IL-4 would inhibit the development of acute GVHD and pro-
mote chronic GVHD development. Indeed, a relatively strong IL-4
response in irradiated human cancer patient recipients of allogeneic
bone marrow is associated with less severe GVHD than develops in pa-
tients who have less of an IL-4 response [8]. In addition, IL-4 produced
by basophils, NKT cells, and conventional CD4+ T cells has been associ-
ated with suppression of GVHD in mouse models [9–12] and treatment
with exogenous IL-4 has some suppressive effect on acute GVHD [9].
However, no formal studies have investigated the timing or dose re-
quirements of the IL-4 effects or have determined whether acute
GVHD suppression is mediated predominantly through direct effects
on donor T cells or through effects on host cells; issues that have
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important implications for the use of IL-4 or IL-4-secreting cells to pre-
vent or ameliorate GVHD.
To investigate these issues, we used amodel in which acute GVHD is
induced by injecting C57BL/6 (B6) CD4+ and CD8+ T cells into (C57BL/
6 × DBA/2)F1 (BDF1) mice (B6 ➔ DBF1) [13] and treated these mice
with complexes prepared by mixing IL-4 with a neutralizing anti-IL-4
mAb. These complexes (IL-4C) prevent the excretion and catabolism
of IL-4 and slowly dissociate in vivo to greatly extend IL-4 half-life
[14]. We observed that IL-4C can completely inhibit acute GVHD with-
out skewing towards a chronic GVHD phenotype at two weeks. This ef-
fect is due to a complete suppression of donor CD8+ CTL maturation,
requires administration of IL-4C close to the time of donor cell transfer
and appears to be mediated predominantly through IL-4 effects on
host rather than donor T cells.
2. Materials and methods
2.1. Mice
6–8week oldmale C57BL/6 J(H-2b) donormice and B6D2F1J (BDF1)
(H-2b/d) recipient host mice were purchased from The Jackson Labora-
tory (Bar Harbor, ME). IL-4Rα-deficient mice on BALB/c and C57BL/6
backgrounds were a gift of Dr. Frank Brombacher, University of
Capetown, South Africa, and were bred to each other to generate
(BALB/c × C57BL/6)F1 IL-4Rα-deficient mice. All animal procedures
were pre-approved by the Institutional Animal Care andUse Committee
at the Uniformed Services University of Health Sciences.
2.2. Induction of GVHD
Single cell suspensions of donor strain splenocytes were prepared as
described [15] and transferred into age matched BDF1 hosts by tail vein
injection. The percentages of donor CD4+ and CD8+ T cells populations
were analyzed by flow cytometry and donor inoculum adjusted prior to
transfer such that all F1 mice received ~5 × 106 donor CD8 T cells. Typ-
ically, this required 55–65 × 106 unfractionated donor splenocytes. For
all experiments, n= 5 recipient F1 host mice/group.
2.3. IL-4C preparation
IL-4Cwere composed of IL-4 (Peprotech, RockyHills, NJ) and anti-IL-
4 mAb (BVD4-1D11.2) purified from mouse ascites. IL-4 was mixed
with anti-IL-4 mAb at a 1:5 (e.g. I μg IL-4 with 5 μg anti-IL-4 mAb) for
5 min at 4 °C and the resulting IL-4C were then diluted to the desired
concentration with 1% autologous mouse serum in PBS. It has been
Fig. 1. IL-4C treatment prevents acute GVHD in a dose-dependent manner. Acute GVHDwas induced in BDF1 hosts as described inMethods. Mice either received no further treatment or
received 10 μg, 3 μg, 1 μg or 0.3 μg of IL-4C on days 0, 3 and 6 after donor cell transfer. At day 14, F1 spleens were assessed by flow cytometry for numbers of engrafted donor (A) CD4+ and
(B) CD8+ T cells and (C) surviving host B cells, (D) CD4+ T cells and (E) CD8+ T cells. Serum IFN-γ levels are shown in (F) as described inMethods. Values represent groupmean± SE. For
all experiments, n= 5/grp). For all figures, *p b 0.05, **p b 0.01, ***p b 0.001. For clarity, only the relevant significant comparisons are marked.
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previously shown that thismethod saturates the anti IL-4mAbwith IL-4
and the IL-4C have strong and prolonged IL-4 agonist activity [11].
2.4. Flow cytometric analysis
Spleen cells were first incubated with anti-murine Fcγ receptor II/III
mAb, 2.4G2 for 10min and then stained with saturating concentrations
of Alexa Fluor 488-conjugated, APC-conjugated, biotin-conjugated, PE-
conjugated, FITC-conjugated, PerCPCy5.5-conjugated, Alexa Fluor 647-
conjugated or Pacific Blue-conjugated mAb against CD3, CD4, CD8,
CD19, B220, H2-Kb, I-Ab, H-2Kd, I-Ad, CD11b and CD11c, CD44, CD62L,
CXCR5, ICOS, PD1, CCR7, KLRG-1, and mPDCA purchased from either
BD Biosciences (San Jose, CA), BioLegend (San Diego, CA), eBioscience
(San Diego, CA), or Invitrogen (Carlsbad, CA). Biotinylated primary
mAb were detected using PE-Texas Red-streptavidin (BD Biosciences,
San Jose, CA). Cells were fixed in 1% paraformaldehyde before reading.
Ex vivo intracellular staining for perforin (pfp), IFN-γ and TNF (MP6-
XT22) were performed as previously described [15] using antibodies
and reagents purchased fromBDBiosciences (San Jose, CA) or Biolegend
(San Diego, CA). Briefly, staining was performed according to the
manufacturer's instructions as previously described [16]. Importantly,
there was no in vitro re-stimulation or use of Golgi blocking agents. Fol-
lowing completion of the staining protocol, cells were analyzed by flow
cytometry immediately. FoxP3 and KI-67 staining was performed as
previously described [15] using fixation buffer (cat# 00-8222-49) and
permeabilization buffer10X (cat# 00-8333-56) from eBioscience. Rep-
resentative staining and dot plots using this approach have been previ-
ously published [1,16,17].
Multi-color flow cytometric analyses were performed using a BD
LSRII flow cytometer (BD Biosciences, San Jose, CA). Gating strategies:
lymphocytes were gated by forward and side scatter and fluorescence
data were collected for a minimum of 10,000 gated cells. Studies of
donor T cells were performed on a minimum of 5000 cells collected
using a lymphocyte gate that was positive for CD4 or CD8 and negative
for MHC class I of the uninjected parent (H-2Kd negative). B cells were
gated as positive for B220 and either positive (host origin) or negative
(donor origin) for MHC Class II of the uninjected parent (I-Ad). Short
lived effector CD8+ CTL were assessed as KRLG-1 positive, CCR7 nega-
tive gated donor CD8+ T cells. Host DC and macrophages were identi-
fied as I-Ad positive and CD11c or CD11b positive respectively using a
broad forward and side scatter gate. DC were further gated as CD3/
CD19 negative, CD11c positive and either mPDCA positive or CD8 posi-
tive. Myeloid DC were identified as CD3 negative, CD11c/CD11b posi-
tive. PMNs were identified as CD11b+ cells with greater FSC/SSC than
lymphocytes. For Tfh cells, the donor and host CD4+ cells were gated
as described above and the PD-1+ sub-population then gated and ana-
lyzed for cells that were positive for both ICOS and CXCR5. Gating strat-
egies and representative staining profiles are shown in Supplemental
Figs. 1–5. Representative staining patterns for host CD4 and CD8 T
cells expressing both KI-67 and Foxp3 are shown in Supplemental Fig. 6.
Fig. 2. IL-4C acts early after donor cell transfer to suppress acute GVHD. Acute GVHD was induced as described in Fig. 1 and in Methods. Mice either received no further treatment or
received 1 μg IL-4C on days 0, 3 and 6; or a single dose of 1 μg IL-4C on day−3, 0, 3 or 6. At day 14, spleens were analyzed for (A) donor CD4+ T cells, (B) donor CD8+ T cells, (C) host
B cells, (D) host CD4+ T cells (E) host CD8+ T cells and (F) serum IFN-γ levels as described for Fig. 1.
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2.5. Cytokine expression by real time PCR
Real time PCR was performed as described [15]. Briefly, splenocytes
(1× 107)were homogenized in 1ml of RNA-STAT-60 (Tel-Test, Friends-
wood, TX). cDNAwas synthesized frommRNA using TaqMan® Reverse
Transcription Reagents kit (Applied Biosystems, Foster City, CA). Real-
time PCR was performed using pre-made primers and probes from
TaqMan® Gene Expression Assays and TaqMan® Universal PCR Master
Mix (Applied Biosystems) for the following targets: IFN-γ, IL-10, IL-21,
IL-4, OAS, MX-1 with 18 s rRNA as an internal control. The calculation
of relative gene expression differences was done by comparative 2−Δ
ΔCT method. The result was expressed as fold change in the experimen-
tal groups compared to uninjected B6D2F1 control.
2.6. In vivo cytokine capture assay (IVCCA)
Serum IFN-g was quantitated using the IVCCA (BD PharMingen,
San Diego, CA) [18,19] as previously described [20]. Briefly, mice
are injected i.v. with 10 μg of a biotin-labeled neutralizing mAb
to IFN-γ, then bled 1 day later. Concentrations of biotin-mAb–
IFN-γ complexes are measured by ELISA, using microtiter plate
wells coated with a mAb to an epitope on the cytokine that is
not blocked by the injected biotin-labeled mAb. Biotin-labeled
mAb–cytokine complexes in serum samples or standards are de-
tected with streptavidin-HRP followed by a TMB substrate solu-
tion that generates a luminescent compound when cleaved by
HRP.
Fig. 3. IL-4C impairs T cell upregulation of thematurationmarker CD44. Acute GVHDwas induced as in Fig. 1. Mice either received no further treatment or were treated with 5 μg of IL-4C
on days, 0, 3 and 6. At day 14 donor, F1 spleens were analyzed by flow cytometry for total numbers of: (A) host B cells, (B) host CD4+ T cells, (C) donor CD4+ T cells and (D) donor CD8+ T
cells. The percentage of CD44 high cells is shown for (E) donor CD4+ T cells, (F) donor CD8+ T cells, (G) host CD4+ T cells and (H) host CD8+ T cells. Values represent group mean ± SE.
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2.7. Statistical analysis
Statistical comparisons were performed using Prism 5.0 (Graphpad
Software, San Diego, CA). Mice were tested individually and data are
expressed as groip mean ± SEM. Statistical significance between two
groups was analyzed using Student's t-test. For multiple comparisons,
two-way ANOVA with an additional Sidak-Bonferoni post-test was
used. p-values b 0.05 were considered as statistically significant.
3. Results
3.1. IL-4 C treatment prevents acute GVHD and inhibits donor T cell survival
To determine whether skewing the cytokine milieu with IL-4 alters
outcome in B6➔ F1 acute GVHD, we administered a broad dose range
of IL-4C at the time of donor cell transfer and 3 and 6 days later and
assessed spleens at day 14. Typical features of acute GVHD were seen
in B6 ➔ BDF1 mice that did not receive IL-4C, including both donor
CD4+ and CD8+ T cell engraftment (Fig. 1A, B, bar 1) along with pro-
found, significant elimination of host B cells and host CD4+ T cells and
to a lesser extent, host CD8+ T cells (Fig. 1C–E, bars 2 vs. 1 respectively).
In the p➔ F1model, host B cells are themost sensitive cell type to elim-
ination by donor CD8+ CTLs, followed by host CD4+ T cells, host DC and
lastly, host CD8+ T cells, which along with host NK cells mediate the
counter regulatory host-vs.-graft (HVG) response and limit donor T
cell engraftment [20]. IL-4C treatment significantly altered the acute
GVHD phenotype. At doses of 10 or 3 μg (IL-4 content of IL-4C), donor
CD4+ and CD8+ T cell numbers were profoundly decreased (Fig. 1A,
B, bars 2 and 3 vs. 1) and elimination of host B cells, CD4+ T cells and
CD8+ T cells was prevented (Fig. 1C–E, bars 3 and 4 vs. 2, p b 0.05;
bars 3 and 4 vs. 1, p= ns). At a 1 μg dose of IL-4C, GVHD mice showed
no significant decrease in the number of donor CD4+ T cells and ~40% of
typical donor CD8+ T cell number (Fig. 1A, B, bar 4), with preservation
of host B cells and CD4+ T cells and a significant increase in host CD8+
T cells (Fig. 1C–E, bar 5). Most effects of IL-4C on acute GVHD were
lostwhen the IL-4C dosewas reduced to 0.3 μg. Similarly, the stimulato-
ry effect of GVHD on IFN-γ secretion 7 days after donor cell transferwas
suppressed in a dose-dependent manner by IL-4C (Fig. 1F). Taken to-
gether, these data suggest that high dose IL-4 leads to the loss of
donor T cells from the host spleen, while a lower dose permits some
donor CD8+ T cell survival but inhibits their ability to kill host cells.
3.2. IL-4 must act early after donor cell transfer to suppress acute GVHD
To determine if there is a critical time for IL-4C suppression of acute
GVHD, we compared the effects of a single, vs. every 3 day 1 μg dose of
IL-4C. Mice received a single IL-4C dose on day−3, 0, 3 or 6 relative to
donor cell transfer and spleens were assessed on day 14. Untreated
(control) acute GVHD mice exhibit engraftment of donor CD4+ and
CD8+ T cells (Fig. 2A, B, bar 1) along with significant elimination of
host B cells, CD4+ T cells and CD8+ T cells compared to normal,
uninjected F1 mice (Fig. 2C–E, bars 2 vs. 1 respectively). Mice treated
with IL-4C every 3 days (positive control) exhibited donor CD4+ and
CD8+ T cell engraftment comparable to mice that received donor cells
Fig. 4. IL-4C blocks cytokine genes associated with acute GVHD. Using the same cohort described in Fig. 3, F1 spleens were analyzed by RT-PCR at day 14 for expression of the following
cytokine genes: (A) IFN-γ, (B) IL-21, (C) Mx1, (D) OAS, (E) IL-10 and (F) IL-4.
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without IL-4C (Fig 2A, B, bars 6 vs. 1 respectively), yet not only had no
elimination of host cells but also significantly more host B and CD8+ T
cells than even mice that had received neither donor cells nor IL-4C
(Fig. 2C–E, bars 7 vs. 1); they also had partial suppression of the
GVHD-induced IFN-γ response (Fig. 2F, bars 7 vs. 2). These observations
strengthen the conclusion drawn from similar treatment with IL-4C in
Fig. 1 that a relatively low dose of IL-4C inhibits donor CD8+ T cell cyto-
toxic function without killing these cells. Similarly, a single 1 μg dose of
IL-4C, administered on theday of donor cell transfer (Day0), did not sig-
nificantly alter donor T cells number (Fig. 2A, B, bars 1 vs. 3), but
significantly impaired the IFN-γ response and host B cell and CD4+
and CD8+ T cell elimination (Fig. 2C–F, bars 2 vs 4). Administration of
IL-4C on any of the other time points boosted donor T cell engraftment
without altering host B cell elimination, although there was some pro-
tective effect on host CD4+ and possibly CD8+ T cells, which are more
resistant to elimination than B cells. Administration of a single IL-4C
dose at all time points studied decreased the IFN-γ response to GVHD
by approximately 25–30%, while multiple doses of IL-4C decreased
this response by approximately 60% (Fig. 2F). Taken together, these re-
sults suggest that IL-4 acts predominantly during the initial activation
Fig. 5. IL-4C treatment blocks donor T cell expression of effector CTL markers. Acute GVHD was induced as described in Fig. 1. Mice either received no further treatment or were treated
with 5 μg of IL-4C on days 0, 3 and 6 or 5 μg of IL-4C only on day 0. At 10 days after donor cell transfer, F1 spleens were analyzed for total numbers of donor (A) CD4+ and (B) CD8+ T cells;
the percentage of donor CD8+ T cells expressing intracellular (C) TNF (D) IFN-γ, (E) perforin; the percentage of donor CD8+ T cells expressing (F) KLRG-1 by surface staining; and total
numbers of (G) donor Tfh cells and (H) PMNs. Values represent group mean ± SE.
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and proliferation of donor T cells to prevent their differentiation into
host MHC-specific CTLs and that IFN-γ is not sufficient for full CTL
differentiation.
3.3. IL-4 impairs donor CTL marker expression and host Tfh expansion
To further evaluatewhether the reduced number of engrafted donor
T cells matures normally when mice are treated with a relatively high
IL-4C dose, we examined day 14 donor T cell CD44 expression in mice
treated with 5 μg of IL-4C on days 0, 3 and 6. As previously seen, IL-4C
treatment completely blocked elimination of host B cells and CD4+ T
cells (Fig. 3A, B) and CD8+ T cells (data not shown) on day 14, in asso-
ciationwith significant reductions in donor CD4+ and CD8+ T cell num-
bers (Fig. 3C, D) and decreases in the percentages of both donor (Fig. 3E,
F) and host (Fig. 3G, H) T cells that express high levels of the activation
marker, CD44. These results suggest that IL-4C impairs both the GVH re-
action and the reciprocal host T cell-mediated HVG response by
preventing the maturation of effector T cells. Analysis of cytokine gene
expression at day 14 demonstrated that high dose IL-4C blocks acute
GVHD-associated elevations in IFN-γ, OAS, MX-1, IL-21 and IL-10 gene
expression, as well as the acute GVHD-associated suppression of IL-4
gene expression (Fig. 4).
We then addressed the maturational status of engrafted donor T
cells at 10 days post-transfer, a time when donor CTL activity typically
peaks in acute GVHD [20]. When examined at this time point, IL-4C
treatment (5 μg on days 0, 3 and 6) had already reduced the number
of donor CD4+ and CD8+ T cells by ~90% (Fig. 5A, B). A similar but
less pronounced effect was seen with a single 5 μg dose of IL-4 at day
0. Among surviving donor T cells, the percentage that expressed TNF
was significantly suppressed, although the percentage that expressed
Fig. 6. IL-4C does not prevent donor T cell splenic homing. Acute GVHDwas induced as in Fig. 1 andmice were either untreated or treatedwith 5 μg of IL-4C on days 0 and 3. At day 5 after
donor cell transfer, F1 spleens were analyzed for total numbers of donor (A) CD4+ and (B) CD8+ T cells; the percentages of donor (C) CD4+ or (D) CD8+ T cells that expressed CD25; the
percentages of donor (E) CD4+ or (F) CD8+ T cells that expressed high levels of CD69; and the percentages of donor (G) CD4+ or (H) CD8+ T cells that expressed Ki67.
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other markers associated with CTL function (KLRG-1, IFN-γ, and
perforin) was unchanged or increased Fig. 5C–F). The effects of IL-4C
at this time were not restricted to donor CD8+ T cells; numbers of
donor CD4+ Tfh were also strikingly reduced (Fig. 5G). By contrast, IL-
4C in either dosing regimen significantly boosted the number of PMN
vs. control acute GVHD mice (Fig. 5H) without significantly altering
splenic macrophage number (data not shown).
3.4. IL-4C does not prevent donor T cell homing to the host spleen or the ini-
tial activation of donor T cells
Because treatment with a relatively high dose of IL-4C causes the
loss of almost all donor CD8+ T cells 10–14 days after cell transfer, it
was possible that IL-4 suppresses donor T cell homing to the spleen.
To evaluate this possibility, we determined donor T cell number and ac-
tivation state 5 days after donor cell injection in mice that were or were
not also treatedwith 5 μg of IL-4C on days 0 and 3. Although the number
of donor CD4+ and CD8+ T cells recovered from the host spleenwas sig-
nificantly reduced by IL-4C treatment, large numbers of donor T cells
were still detected in IL-4C-treated mice 5 days after donor cell transfer
(Fig 6A, B). Furthermore, IL-4C did not reduce the percentage of donor T
cells that expressed the activation marker CD25 (Fig. 6C, D). It also in-
creased the percentage of donor cells expressing a second activation
marker, CD69 (Fig. 6E, F) and had little effect on the percentage of pro-
liferating (Ki-67+) cells among the surviving donor T cells. Thus, inhibi-
tion of donor cell homing and initial activation by IL-4C is atmost partial
and cannot account for the complete suppression of GVHD observed at
day 14.
3.5. IL-4C blockade of acute GVHD is not mediated primarily by a direct ef-
fect on donor T cells
The long period of increased IL-4 concentration that is required to
decrease donor T cell number and activity raised the possibility that
the effect of IL-4 on donor T cells might be indirect. To determine
whether IL-4C suppresses acute GVHD by acting directly on donor T
cells, we compared the ability of 5 μg of IL-4C on days 0, 3 and 6 to
block acute GVHD following transfer of either wild-type (WT) or IL-
4Rα-deficient C57BL/6 donor cells (Fig. 7). Fourteen days after donor
cell transfer, typical features of acute GVHD were seen in WT ➔ F1
mice, including engraftment of both donor CD4+ and CD8+ T cells
(Fig. 7A, B, bar 1) and profound elimination of host B cells, CD4+ and
CD8+ T cells vs. normal F1 (Fig. 7C–E, bars 1 vs. 2). Although treatment
with 5 μg of IL-4C on days 0, 3 and 6 did not block donor T cell engraft-
ment in this experiment (Fig. 7A–B, bar 2), elimination of host B cells
and CD4+ T cells was completely abrogated (Fig. 7C–D, bar 3) as in
Fig. 7. IL-4C blockade of acute GVHD does not require donor T cell IL-4R signaling. Acute GVHD was induced in WT F1 mice following the transfer of B6 WT or B6 IL-4Rα KO donor
splenocytes. GVHD mice were either untreated or received 5 μg of IL-4C on days 0, 3 and 6. At day 14, F1 hosts were analyzed by flow cytometry for total numbers of (A) donor CD4+
T cells, (B) donor CD8+ T cells, (C) host B cells, (D) host CD4+ T cells, and (E) host CD8+ T cells.
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our previous experiments that treated mice with 1–10 μg of IL-4C (Figs.
1–3). Moreover, host CD8+ T cell number was significantly increased,
consistent with a direct stimulatory effect of IL-4C on host CD8+ T
cells (Fig. 7E, bar 3). IL-4Rα-deficient➔ F1mice also developed the typ-
ical acute GVHD phenotype, although donor T cell engraftmentwas sig-
nificantly greater than with wild-type C57BL/6 donor T cells (Fig. 7A, B
(bars 3 vs. 1), with striking elimination of host B cells and CD4+ T
cells (Fig. 7C, D, bars 4 vs 1). Nevertheless, IL-4C treatment of mice re-
ceiving IL-4Rα-deficient donor T cells significantly impaired donor T
cell engraftment (Fig. 7A–B, bars 3 vs. 4), completely abrogated host B
cell and CD4+ T cell elimination and significantly increased host CD8+
T cell number (Fig. 7C–E, bars 4 vs. 5). Thus, IL-4 suppression of acute
GVHD does not require direct stimulation of donor T cells by this
cytokine.
To determine if an IL-4 effect on host cells is required for IL-4 sup-
pression of acute GVHD, we developed an acute GVHD model in
which the host, rather than the donor, is IL-4-unresponsive. Because
BALB/c and C57BL/6, but not DBA IL-4Rα-deficient mice were available,
we switched to a parent➔ F1model that used C57BL/6 donor T cells and
(BALB/c × C57BL/6)F1 (CB6F1) recipients. Preliminary experiments
confirmed that an inoculum of ~5 × 106 CD8+ and 8–10 × 106 CD4+ T
cells could induce acute GVHD in this model. We then compared the
ability of WT B6 donor cells to induce acute GVHD in CB6F1 WT or IL-
4Rα-deficient (KO) mice that had or had not been treated with 5 μg of
IL-4C on days 0, 3 and 6 (Fig. 8). The ability to fully interpret the results
of this study is limited by significantly greater donor CD4+ and CD8+ T
cell engraftment in wild-type vs. IL-4Rα KO mice (despite transferring
the same number of donor cells) in the absence of exogenous IL-4
(Fig. 8A, B, bars 1 vs. 2). These differences were associated with signifi-
cantly greater elimination of host cells by the wild-type donor cells.
Acute GVHD was associated with a loss of ~90% of host B cells in wild-
type hosts and an ~75% loss of B cells in IL-4Rα-deficient hosts with
comparable effects seen for host CD4+ and CD8+ T cells (Fig. 8C–E,
bars 3 and 4). As expected, IL-4C treatment completely blocked B cell
elimination when acute GVHD was induced in wild-type hosts and, in
fact, increased host splenic B cell number to ~130% of control (45 × 106-
/spleen) in thesemice (Fig. 8C, bars 5 vs.1), while IL-4C only partially re-
stored splenic B cell number in IL-4Rα-deficient hosts to
32 × 106/spleen (55% of the uninjected IL-4Rα-deficient F1 control
number) (Fig. 8C, bars 6 vs. 2). Similarly, IL-4C restored host CD4+ T
cell numbers to supra-normal (175%) levels in wild-type hosts (Fig.
8D, bars 5 vs.1) yet only partially (78%) restored host CD4+ T cell
Fig. 8. IL-4C partially inhibits acute GVHD in the absence of host IL-4Ra. Acute GVHD was induced following the transfer of B6WT splenocytes into either CB6F1WT or CB6F1 IL-4Rα KO
hosts. GVHDmice received no further treatment or received 5 μg of IL-4C on days 0, 3 and 6. On day 14,micewere assessed by flow cytometry for total numbers of (A) donor CD4+ T cells,
(B) donor CD8+ T cells, (C) host B cells, (D) host CD4+ T cells, and (E) host CD8+ T cells.
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numbers in IL-4Rα-deficient hosts (Fig. 8D, bars 6 vs. 2). By contrast, IL-
4C treatment significantly boosted host CD8+ T cell numbers over un-
treated F1 in both wild-type (~3-fold) and IL-4Rα-deficient (2-fold)
hosts (Fig. 8E, bars 2 vs. 6; 1 vs. 5), demonstrating that IL-4C stimulates
host CD8+ T cell expansion even when these cells cannot directly re-
spond to IL-4. Similar to Fig. 7, IL-4C abrogation of acute GVHD occurred
without the characteristic reduced donor CD4 T cell survival seen in Figs.
1 and 2. Thus, although IL-4C blocks acute GVHD in both wild-type
B6 ➔ CB6F1 and wild-type B6 ➔ BDF1, the restoration of host B cell
and CD4+ T cell numbers is complete inwild-type hosts and incomplete
in IL-4Rα-deficient hosts with levels significantly reduced as compared
to untreated IL-4Rα-deficient F1 controls (Fig. 8C, D, bars 6 vs. 2).
The partial restoration of host B cell number in IL-4Rα-deficient re-
cipient mice by IL-4C suggests that IL-4 can suppress cytotoxic GVHD,
to a limited extent, through direct effects on donor T cells. Taken togeth-
er with the more complete suppression of acute GVHD by IL-4C when
only host cells are IL-4-responsive (Fig. 7), our results indicate that IL-
4 predominantly suppresses acute GVHD through effects on host cells,
and to a lesser extent through effects on donor T cells.
3.6. IL-4C suppression of acute GVHD phenotype is not primarily NK cell-
mediated
Both CD8+ T cells and NK cells contribute to the counter regulatory
host-vs. graft (HVG) response that impairs donor T cell (particularly
CD8+) engraftment and the ensuing GVHD [17,20]. Because IL-4 is
known to activate NK cells [21], which can suppress CD8+ T cell activity
and survival, it seemed possible that this cytokine could suppress acute
GVHD by activating NK cells. To evaluate this possibility, we examined
the ability of NK cell depletion to block the suppressive effect of IL-4C
on acute GVHD. Treatment with anti-NK1.1 mAb depleted N90% of NK
cells compared to untreatedmice (data not shown) and significantly in-
creased donor CD4+ T cell engraftment in both control acute GVHD and
IL-4C treated acute GVHD (Fig. 9A, bars 1 vs. 2 and 3 vs. 4). A similar but
milder (and non-significant) effect was seen for donor CD8 T cell en-
graftment (Fig. 9B, bars 1 vs. 2 and 3 vs. 4). This increase in donor T
cell numbers is consistentwith a loss of theNK portion of the down-reg-
ulatory HVG response. Nevertheless, IL-4C significantly impaired donor
T cell engraftment for both control and NK-depleted GVHD mice (Fig.
Fig. 9.HostNK cells are not required for IL-4C blockade of acute GVHD. Acute GVHDwas induced as described [20] using B6WTdonors and BDF1WThosts. Host NK cells were depleted as
described inMethods. F1micewere either untreated or received 5 μg of IL-4C on days 0, 3 and 6 and spleens analyzed by flow cytometry at day 14 for total numbers of: (A) donor CD4+ T
cells, (B) donor CD8+ T cells, (C) host B cells, (D) host CD4+ T cells and (E) host CD8+ T cells.
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9A, B, bars 1 vs. 3 and 2 vs. 4). IL-4C treatment also significantly im-
paired acute GVHD-mediated elimination of host B cells, CD4+ T cells
and CD8+ T cells in both control acute GVHD (Fig. 9C–E, bars 2 vs. 4)
and NK-depleted acute GVHD (Fig. 9C–E, bars 3 vs. 5). Thus, IL-4 does
not suppress acute GVHD primarily by activating NK cells.
3.7. IL-4C promotes expansion of host CD8+ T cells
Because host CD8+ T cells can limit GVHD by either differentiating
into Tc2 cells [22] or by participating in a HVG reaction (17, 20) and
IL-4 can stimulate CD8+ T cell proliferation in the absence of GVHD
[23], we evaluated whether IL-4C has a stimulatory effect on host
CD8+ T cells in the context of acute GVHD. Using the mice described
in Fig. 6 that had or had not been treated with 5 μg of IL-4C on days 0
and 3, we determined host T cell number and activation state 5 days
after donor cell injection. Host CD4+ T cell numbers in untreated
acute GVHD mice were modestly but not significantly increased over
control F1 at day 5 whereas IL-4C treatment significantly boosted host
CD4+ T cell numbers over untreated control F1 mice (Fig. 10A). In con-
trast, although the number of host CD8+ T cells was not significantly in-
creased by GVHD at this time point; it was increased by IL-4C treatment
regardless of the presence of GVHD (Fig. 10B), although IL-4C treatment
did not affect the percentage of host T cells expressing CD25 (not
shown). Although GVHD was accompanied by a significant, IL-4-inde-
pendent increase in host CD4+ T cell expression of the early activation
Ag, CD69, IL-4C treatmentwas required to significantly increase theper-
cent of CD69+ host CD8+ T cells in mice undergoing acute GVHD (Fig.
10 C, D). Furthermore, although expression of Ki-67was significantly in-
creased by GVHD in the absence of IL-4C treatment, this treatment in-
duced an additional, significant increase in the percentage of Ki-67+
host CD4+ and particularly CD8+ T cells (Fig. 10 E, F). Thus, IL-4C treat-
ment could contribute to the suppression of acute GVHD by enhancing
host CD8+ T cell activation.
3.8. IL-4C effects on host myeloid cells may contribute to suppression of
GVHD
One possible mechanism for the suppressive effect of IL-4C on acute
GVHD is suppression of MHC class I presentation to donor T cells. Be-
cause this is dependent on host DCs and should occur relatively early
after donor cell transfer, we evaluated the effect of IL-4C on DCs during
acute GVHD 5 days after donor cell transfer, using the cohort described
in Fig. 6. Consistentwith this possibility, IL-4C treatment (5 μg on days 0
and 3) significantly blocked the GVHD-associated expansion of host
pDC, CD8a+ DC, and myeloid DC seen 5 days after cell transfer (Fig.
11A–C). Additionally, IL-4C treatment significantly increased the total
Fig. 10. IL-4C promotes expansion of host T cells, particularly CD8+ T cells. Flow cytometrywas used to analyze the cohort described in Fig. 6 for: numbers of (A) host CD4+ T cells and B)
host CD8+ T cells; and the percentages of host CD4+ and CD8+ T cells (C + D) that upregulated CD69 or (E + F) expressed Ki-67.
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numbers of Foxp3+ host CD4+ and CD8+ T cells (Fig. 11D + E) and
numbers of proliferating Tregs (Foxp3+, Ki-67+) for both CD4+ and
CD8+ host T cells vs. control F1 mice (Fig. 11F, G).
An additional possible mechanism for IL-4C suppression of acute
GVHD could be stimulation of myeloid derived suppressor cells
(MDSCs), which have a monocyte/macrophage or neutrophil pheno-
type and are known to inhibit CD8+ CTL function and survival. IL-4C
treatment considerably inhibited the number of splenic CD11b+-
CD11c− cells that had light scatter characteristics typical of monocyte/
macrophages and did not increase the PMN population 5 days after
Fig. 11. IL-4C blocks GVHD associated expansion of host dendritic cell subsets andmacrophages. The cohort described in Fig. 6 was evaluated by flow cytometry for host DC subsets, Tregs,
macrophages and PMNusing parameters described inMethods for (A) pDC, (B) CD8a+ DC, (C)myeloid DC, (D) CD4+ Foxp3+ T cells (E) CD8+ Foxp3+ T cells, (F) Ki-67+ Foxp3+ CD4+ T
cells, (G) Ki-67+ Foxp3+ CD8+ T cells, (H) macrophages (CD11b+, CD11c−) and (I) PMNs.
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donor cell administration (Fig. 11H, I)., but increased the PMN popula-
tion 10 days after donor cell administration (Fig. 5H).,
4. Discussion
Because type 1 and inflammatory cytokines are associated with
acute GVHD pathogenesis and IL-4 can inhibit the production and ef-
fects of these cytokines, we evaluated whether treatment with exoge-
nous IL-4 could suppress acute GVHD development. Our results
establish that IL-4 can completely suppress acute GVHD, without induc-
ing chronic (autoimmune) GVHD during the 2 week period after donor
cell administration. This observation is consistent with previous reports
that: [1] IL-4 produced by NKT cells or basophils can inhibit acute mu-
rine GVHD in models that differ from the one used in our studies [9–
12]; [2] administration of a relatively low dose of IL-4C prior to and at
the time of cell transfer partially inhibits acute GVHD in one of these
models [9]; and [3] relatively large numbers of IL-4 secreting cells are
associated with reduced severity of acute GVHD in people treated
with irradiation followed by allogeneic bone marrow [8]. We have ex-
tended these observations by determining the timing and doses re-
quired for optimal IL-4 suppression of acute GVHD and providing
insight into the mechanisms responsible for IL-4's suppressive effects.
Our results show that this suppressive effect requires IL-4 adminis-
tration close to the time of donor cell transfer, but is increased if IL-4
continues to be administered for 5–6 days after cell transfer. Although
this raised the possibility that IL-4 works by limiting the homing of
donor T cells to the host spleen, IL-4 has little effect on the numbers of
these donor CD8+ T cells in the host spleen soon after cell transfer. In-
stead, relatively high doses of IL-4 interfere with donor CD8+ T cell sur-
vival while lower doses of IL-4 allow survival but inhibit differentiation
into effector CD8+ CTLs. Importantly, the main inhibitory effect of IL-4
on acute GVHD results from an effect on host cells, rather than donor
cells, even though CD4+ and CD8+ T cells express considerable IL-4Rα
and respond strongly to IL-4. This result was demonstrated by showing
that the suppressive effect of IL-4C is not diminishedwhen IL-4Rα-defi-
cient donor cells are used to induce GVHD and is consistent with our
previous observation that the acute GVHD-enhancing effect of IFN-γ is
actually increased when this disease is induced by transfer of IFN-γ R-
deficient T cells. Similarly, IL-4C abrogation of acute GVHD in WT mice
could be seen both in the absence (Figs. 1 & 2) and presence (Figs. 7 &
8) of donor CD4 T cells. However, IL-4C treatment still has a partial sup-
pressive effect on acute GVHD when parental IL-4Rα-sufficient T cells
are transferred into IL-4Rα-deficient F1 hosts. This is consistent with
previous observations that suggest a direct suppressive effect of IL-4
on CTL differentiation [24]. Taken together, these observations indicate
that IL-4 suppresses CD8+ CTL maturation and acute GVHD by more
than one mechanism, although the effect on host cells appears to
predominate.
This conclusion led us to try to identify the host cell andmechanism
involved in the IL-4 suppressive effect. One possibility, that IL-4 inhibits
donor CD8+ T cells by stimulating host NK cells, was consistent with
previous reports of IL-4 stimulatory effects on NK cells and NK cell sup-
pressive effects on GVHD, but was not borne out by our data; elimina-
tion of host NK cells failed to decrease the suppressive effect of IL-4 on
acute GVHD. Another possibility; that IL-4 acts primarily by making
host cells resistant to donor CTLs is also inconsistent with our data, be-
cause it doesn't explain IL-4 suppression of the differentiation of donor
cells into cells that have CTL markers or the loss of donor CD8+ T cells
when mice are treated with high doses of IL-4.
The requirement for early administration of IL-4 to suppress acute
GVHD, even through it takes ~10 days for the development of potent
CTLs in our GVHDmodel, suggested that IL-4 acts through an early pro-
cess in T cell activation and differentiation, such as Ag presentation.
Consistent with this, IL-4 treatment had a strong suppressive effect on
the number of all populations of splenic dendritic cells. Although we
have not evaluated whether IL-4 treatment also affects the Ag
presenting ability of these cells, a previous in vitro study demonstrated
that IL-4 suppresses T cell proliferation in an allogeneic mixed lympho-
cyte reaction predominantly through an effect on Ag presenting cells
rather than a direct effect on T cells [9]. This possibility is also consistent
with our previous observation that IFN-γ enhances acute GVHD
through an effect on host cells [25], and thewell established stimulatory
effect of IFN-γ on Ag presenting cell function [26].
We do not, however, favor the view that IL-4 suppression of acute
GVHD is achieved through a single mechanism. In addition to the previ-
ously mentioned evidence that direct IL-4 effects on donor T cells con-
tribute, to some extent, to suppression of acute GVHD, and the
possibility that IL-4 inhibits CD8+ CTL maturation and acute GVHD
through an affect on host Ag presentation, we have observed in other
in vivo models that IL-4 can suppress T cell proliferation and survival
by inducing a large population of myeloid suppressor cells (Morris, SC
et al., manuscript in preparation). This observation is consistent with
the increase in splenic myeloid cells 10 days after donor cell transfer
in mice that have been treated with IL-4 and with the general observa-
tion that individual cytokines typically act in multiple ways to reinforce
a specific biological effect. Our evidence that IL-4 activates and increases
the number of host CD8+ T cells during acute GVHD is also consistent
with the possibility that this cytokine acts through several parallel
mechanisms to suppress acute GVHD, because activated host CD8+ T
cells might amplify the HVG response [17] or differentiate into GVHD-
limiting Tc2 [22]. Taken together, these observations using normal, un-
irradiated hosts provide important mechanistic information about IL-4
effects on the alloantigen-specific CD8+ CTL response in the setting of
an intact immune system and may have clinical relevance when a
strong CD8+ CTL response is undesirable e.g., renal transplantation.
Our results raise the possibility of administering IL-4 or IL-4-producing
cells at the time of transplantation to suppress the development of
host anti-graft CD8+ CTL and acute transplant rejection.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.clim.2017.03.008.
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